Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016, 60400-60405 [2015-25373]

Download as PDF 60400 Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices cannot guarantee that we will be able to do so. CALIFORNIA Monterey County Aeneas Sardine Packing Company Cannery, 300 Cannery Row, Monterey, 15000739 OHIO Hamilton County William Howard Taft National Historic Site (Boundary Increase and Additional Documentation, 2038 Auburn Ave., Cincinnati, 15000753 COLORADO A request to move has been made for the following resource: Routt County INDIANA Hayden Co-Operative Elevator Company, 198 E. Lincoln Ave., Hayden, 15000740 Clay County Indiana State Highway Bridge 46–11–1316, IN 46 over Eel R., Bowling Green, 00000211 DISTRICT OF COLUMBIA District of Columbia Capitol Hill Historic District (Boundary Increase II), Squares 752, 753, 777, 788 bounded by 2nd, 4th & F Sts. NE., Washington, 15000741 Davis, Colonel William Robert, House, 3020 Albemarle St. NW., Washington, 15000742 Young, Browne, Phelps and Springarn Educational Campus Historic District, (Public School Buildings of Washington, DC MPS) 2500 Benning Rd. NE., 704, 820, & 850 26th St. NE., Washington, 15000743 GEORGIA In the interest of preservation a three day comment period has been requested for the following resource: Toccoa Downtown Historic District (Boundary Increase), 118 W. Doyle St., Toccoa, 15000744 Ozaukee County SENATOR (steam screw) Shipwreck, (Great Lakes Shipwreck Sites of Wisconsin MPS) Address Restricted, Port Washington, 15000738 DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–420F] Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016 BILLING CODE 4312–51–P Drug Enforcement Administration, Department of Justice. ACTION: Final order. AGENCY: Carroll County Manning Commercial Historic District, (Iowa’s Main Street Commercial Architecture MPS) 217–411, 413–507, 302– 326 Main, 717–723 3rd, 303 Center & 825 5th Sts., Manning, 15000745 JOINT BOARD FOR THE ENROLLMENT OF ACTUARIES Henry County AGENCY: Benjamin Chapel and Richwoods Cemetery, 1936 Franklin Ave., Trenton, 15000746 Boyle, Hugh and Matilda, House and Cemetery Historic District, 3225 Lexington Ave., Lowell, 15000747 Edwards, Joseph A. and Lydia A., House, 1735 Salem Rd., Salem, 15000748 Garretson, Owen A. and Emma J., House, 1878 335th St., Salem, 15000750 Linn County Cedar Rapids 2nd Avenue SE. Automobile Row Historic District, Roughly 2nd to 3rd Aves., SE., from 6th to 8th Sts., SE., Cedar Rapids, 15000749 Monroe Elementary School Historic District, 3200 Pioneer Ave., SE., Cedar Rapids, 15000751 tkelley on DSK3SPTVN1PROD with NOTICES [FR Doc. 2015–25342 Filed 10–5–15; 8:45 am] Authority: 60.13 of 36 CFR part 60 [FR Doc. 2015–25375 Filed 10–5–15; 8:45 am] IOWA Montgomery County Ellis, William and Amanda J., Farmstead Historic District, 1134 I Ave., Elliott, 15000752 NEW YORK Essex County Helen Hill Historic District, Prescott Place, Helen & Front Sts., Sheppard, Franklin & Clinton Aves., Saranac Lake, 15000754 VerDate Sep<11>2014 Dated: September 21, 2015. Patrick W. McDonough, Executive Director, Joint Board for the Enrollment of Actuaries. BILLING CODE 4830–01–P WISCONSIN Dated: September 16, 2015. Roger Reed, Acting Chief, National Register of Historic Places/National Historic Landmarks Program. Stephens County mathematics, pension law and methodology referred to in 29 U.S.C. 1242(a)(1)(B). A determination has been made as required by section 10(d) of the Federal Advisory Committee Act, 5 U.S.C. App., that the subject of the meeting falls within the exception to the open meeting requirement set forth in Title 5 U.S.C. 552b(c)(9)(B), and that the public interest requires that such meeting be closed to public participation. 18:31 Oct 05, 2015 Jkt 238001 Meeting of the Advisory Committee; Meeting Joint Board for the Enrollment of Actuaries ACTION: Notice of Federal Advisory Committee meeting. The Executive Director of the Joint Board for the Enrollment of Actuaries gives notice of a closed teleconference meeting of the Advisory Committee on Actuarial Examinations. DATES: The meeting will be held on October 30, 2015, from 8:30 a.m. to 5:00 p.m. FOR FURTHER INFORMATION CONTACT: Patrick W. McDonough, Executive Director of the Joint Board for the Enrollment of Actuaries, 703–414–2173. SUPPLEMENTARY INFORMATION: Notice is hereby given that the Advisory Committee on Actuarial Examinations will hold a teleconference meeting on October 30, 2015, from 8:30 a.m. to 5:00 p.m. The meeting will be closed to the public. The purpose of the meeting is to discuss topics and questions that may be recommended for inclusion on future Joint Board examinations in actuarial SUMMARY: PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 This final order establishes the initial 2016 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. SUMMARY: DATES: Effective October 6, 2015. John R. Scherbenske, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: FOR FURTHER INFORMATION CONTACT: Legal Authority The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. Titles II and III are referred to as the ‘‘Controlled Substances Act’’ and the ‘‘Controlled Substances Import and Export Act,’’ respectively, and are collectively referred to as the ‘‘Controlled Substances Act’’ or the ‘‘CSA’’ for the purpose of this action. 21 E:\FR\FM\06OCN1.SGM 06OCN1 Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices tkelley on DSK3SPTVN1PROD with NOTICES U.S.C. 801–971. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while ensuring an adequate supply is available for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety. Section 306 of the Controlled Substances Act (CSA), 21 U.S.C. 826, requires the Attorney General to determine the total quantity and establish production quotas for each basic class of controlled substance in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine to be manufactured each calendar year to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. This responsibility has been delegated to the Administrator of the DEA through 28 CFR 0.100(b). Background The 2016 aggregate production quotas and assessment of annual needs represent those quantities of schedule I and II controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine that may be manufactured in the United States in 2016 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include imports of controlled substances for use in industrial processes. On July 17, 2015, a notice titled, ‘‘Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Proposed Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016’’ was published in the Federal Register. 80 FR 42540. This notice proposed the 2016 aggregate production quotas for each basic class of controlled substance listed in schedules I and II and the 2016 assessment of annual needs for the list I chemicals ephedrine, VerDate Sep<11>2014 18:31 Oct 05, 2015 Jkt 238001 pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before August 17, 2015. Comments Received Twenty comments were received from four DEA-registered manufacturers within the published comment period regarding 17 different schedule I and II controlled substances. The DEA did not receive any comments regarding the proposed assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. Commenters stated that the proposed aggregate production quotas for [1-(5fluoropentyl)-1H-indazol-3yl](naphthalen-1-yl)methanone (THJ– 2201), amphetamine (for sale), codeine (for sale), gamma hydroxybutric acid, levorphanol, marihuana, methylphenidate, N-(1-Amino-3,3dimethyl-1-oxobutan-2-yl)-1-pentyl-1Hindazole-3-carboxamide (ADB– PINACA), N-(1-Amino-3-methyl-1oxobutan-2-yl)-1-(4-fluorobenzyl)-1Hindazole-3-carboxamide (AB– FUBINACA), N-(1-Amino-3-methyl-1oxobutan-2-yl)-1-(cyclohexylmethyl)1H-indazole-3-carboxamide (AB– CHMINACA), N-(1-Amino-3-methyl-1oxobutan-2-yl)-1-pentyl-1H-indazole-3carboxamide (AB–PINACA), N-(1phenethylpiperidin-4-yl)-Nphenylacetamide (acetyl fentanyl), nabilone, oxymorphone (for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate (5-Flouro-PB–22), and Quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB–22) were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. Determination of 2016 Aggregate Production Quotas and Assessment of Annual Needs In determining the 2016 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826(a), and other relevant factors, including the 2015 manufacturing quotas, current 2015 sales and inventories, anticipated 2016 export requirements, industrial use, additional applications for 2016 quotas, as well as information on research and product development PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 60401 requirements. Based on this information, the DEA has determined that adjustments to the proposed aggregate production quotas for codeine (for sale), hydromorphone, marihuana, methylphenidate, and N-(1phenethylpiperidin-4-yl)-Nphenylacetamide (acetyl fentanyl) are warranted. This final order reflects those adjustments. Regarding [1-(5-fluoropentyl)-1Hindazol-3-yl](naphthalen-1yl)methanone (THJ–2201), amphetamine (for sale), gamma hydroxybutric acid, levorphanol, N-(1-Amino-3,3-dimethyl1-oxobutan-2-yl)-1-pentyl-1H-indazole3-carboxamide (ADB–PINACA), N-(1Amino-3-methyl-1-oxobutan-2-yl)-1-(4fluorobenzyl)-1H-indazole-3carboxamide (AB–FUBINACA), N-(1Amino-3-methyl-1-oxobutan-2-yl)-1(cyclohexylmethyl)-1H-indazole-3carboxamide (AB–CHMINACA), N-(1Amino-3-methyl-1-oxobutan-2-yl)-1pentyl-1H-indazole-3-carboxamide (AB– PINACA), nabilone, oxymorphone (for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate (5-Flouro-PB–22), and Quinolin-8-yl 1-pentyl-1H-indole-3carboxylate (PB–22), the DEA has determined that the proposed aggregate production quotas are sufficient to provide for the 2016 estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. This final order establishes these aggregate production quotas at the same amounts as proposed. As described in the previously published notice proposing the 2016 aggregate production quotas and assessment of annual needs, the DEA has specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, the DEA has included in all established schedule II aggregate production quotas, and certain schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The established aggregate production quotas will reflect these included amounts. This action will not affect the ability of E:\FR\FM\06OCN1.SGM 06OCN1 60402 Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices manufacturers to maintain inventory allowances as specified by regulation. The DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event results in the substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by the DEA. The DEA does not anticipate utilizing the reserve in the absence of these circumstances. In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 1315.11, the Administrator hereby establishes the 2016 aggregate production quotas for the following schedule I and II controlled substances and the 2016 assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Established 2016 quotas (g) Basic class tkelley on DSK3SPTVN1PROD with NOTICES Schedule I (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR–144) ............................................................................. [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone (THJ–2201) ............................................................................... [1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ............................................................... 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone) ................................................................................................. 1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone) ............................................................................................. 1-(1-Phenylcyclohexyl)pyrrolidine .................................................................................................................................................. 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ...................................................................................................................... 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ..................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]piperidine ............................................................................................................................................. 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200) ........................................................................................................ 1-Butyl-3-(1-naphthoyl)indole (JWH–073) ..................................................................................................................................... 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8) ................................................................................... 1-Hexyl-3-(1-naphthoyl)indole (JWH–019) .................................................................................................................................... 1-Methyl-4-phenyl-4-propionoxypiperidine ..................................................................................................................................... 1-Pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678) ............................................................................................................... 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH–203) ..................................................................................................................... 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250) ................................................................................................................. 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398) ..................................................................................................................... 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122) .................................................................................................................... 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19, RCS–4) ............................................................................................................. 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081) ................................................................................................................ 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) .................................................................................................................... 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) ................................................................................................................. 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) ................................................................................................................... 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P) ............................................................................................................... 2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) ................................................................................................................................ 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi-36) ................ 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) .................................................................................................................. 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi-82) ............... 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) ....................................................................................................................... 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi-5) .......................... 2-(Methylamino)-1-phenylpentan-1-one (pentedrone) ................................................................................................................... 2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................ 2,5-Dimethoxy-4-n-propylthiophenethylamine ............................................................................................................................... 2,5-Dimethoxyamphetamine .......................................................................................................................................................... 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ......................................................................................................... 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) .................................................................................................. 3,4,5-Trimethoxyamphetamine ...................................................................................................................................................... 3,4-Methylenedioxyamphetamine (MDA) ...................................................................................................................................... 3,4-Methylenedioxymethamphetamine (MDMA) ........................................................................................................................... 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ....................................................................................................................... 3,4-Methylenedioxy-N-methylcathinone (methylone) .................................................................................................................... 3,4-Methylenedioxypyrovalerone (MDPV) ..................................................................................................................................... 3-Fluoro-N-methylcathinone (3–FMC) ........................................................................................................................................... 3-Methylfentanyl ............................................................................................................................................................................. 3-Methylthiofentanyl ....................................................................................................................................................................... 4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................ 4-Bromo-2,5-dimethoxyphenethylamine (2–CB) ........................................................................................................................... 4-Fluoro-N-methylcathinone (4–FMC) ........................................................................................................................................... 4-Methoxyamphetamine ................................................................................................................................................................ 4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................ 4-Methylaminorex .......................................................................................................................................................................... 4-Methyl-N-ethylcathinone (4–MEC) ............................................................................................................................................. 4-Methyl-N-methylcathinone (mephedrone) .................................................................................................................................. 4-Methyl-a-pyrrolidinopropiophenone (4-MePPP) ......................................................................................................................... 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ................................................................................................... 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog) .................... 5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................ 5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................ 5-Methoxy-N,N-dimethyltryptamine ............................................................................................................................................... Acetyl-alpha-methylfentanyl ........................................................................................................................................................... VerDate Sep<11>2014 18:31 Oct 05, 2015 Jkt 238001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\06OCN1.SGM 06OCN1 25 15 25 25 25 10 45 45 15 45 45 45 45 2 45 45 45 45 45 45 45 30 30 30 30 30 25 30 25 30 15 25 25 25 25 30 30 25 55 50 40 50 35 25 2 2 25 25 25 150 25 25 25 45 25 68 53 25 25 25 2 Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices Established 2016 quotas (g) tkelley on DSK3SPTVN1PROD with NOTICES Basic class Acetyldihydrocodeine ..................................................................................................................................................................... Acetylmethadol .............................................................................................................................................................................. Allylprodine .................................................................................................................................................................................... Alphacetylmethadol ........................................................................................................................................................................ alpha-Ethyltryptamine .................................................................................................................................................................... Alphameprodine ............................................................................................................................................................................. Alphamethadol ............................................................................................................................................................................... alpha-Methylfentanyl ...................................................................................................................................................................... alpha-Methylthiofentanyl ................................................................................................................................................................ alpha-Methyltryptamine (AMT) ...................................................................................................................................................... alpha-Pyrrolidinobutiophenone (a-PBP) ........................................................................................................................................ alpha-Pyrrolidinopentiophenone (a-PVP) ...................................................................................................................................... Aminorex ........................................................................................................................................................................................ Benzylmorphine ............................................................................................................................................................................. Betacetylmethadol ......................................................................................................................................................................... beta-Hydroxy-3-methylfentanyl ...................................................................................................................................................... beta-Hydroxyfentanyl ..................................................................................................................................................................... Betameprodine ............................................................................................................................................................................... Betamethadol ................................................................................................................................................................................. Betaprodine .................................................................................................................................................................................... Bufotenine ...................................................................................................................................................................................... Cathinone ....................................................................................................................................................................................... Codeine methylbromide ................................................................................................................................................................. Codeine-N-oxide ............................................................................................................................................................................ Desomorphine ................................................................................................................................................................................ Diethyltryptamine ........................................................................................................................................................................... Difenoxin ........................................................................................................................................................................................ Dihydromorphine ............................................................................................................................................................................ Dimethyltryptamine ........................................................................................................................................................................ Dipipanone ..................................................................................................................................................................................... Fenethylline .................................................................................................................................................................................... gamma-Hydroxybutyric acid .......................................................................................................................................................... Heroin ............................................................................................................................................................................................ Hydromorphinol .............................................................................................................................................................................. Hydroxypethidine ........................................................................................................................................................................... Ibogaine ......................................................................................................................................................................................... Lysergic acid diethylamide (LSD) .................................................................................................................................................. Marihuana ...................................................................................................................................................................................... Mescaline ....................................................................................................................................................................................... Methaqualone ................................................................................................................................................................................ Methcathinone ............................................................................................................................................................................... Methyldesorphine ........................................................................................................................................................................... Methyldihydromorphine .................................................................................................................................................................. Morphine methylbromide ............................................................................................................................................................... Morphine methylsulfonate .............................................................................................................................................................. Morphine-N-oxide .......................................................................................................................................................................... N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) .................................................................................................. N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (ADB–PINACA) ............................................... N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB–FUBINACA) ................................... N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB–CHMINACA) ............................. N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB–PINACA) ....................................................... N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide (acetyl fentanyl) .............................................................................................. N,N-Dimethylamphetamine ............................................................................................................................................................ Naphthylpyrovalerone (naphyrone) ............................................................................................................................................... N-Benzylpiperazine ........................................................................................................................................................................ N-Ethyl-1-phenylcyclohexylamine .................................................................................................................................................. N-Ethylamphetamine ..................................................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................ Noracymethadol ............................................................................................................................................................................. Norlevorphanol ............................................................................................................................................................................... Normethadone ............................................................................................................................................................................... Normorphine .................................................................................................................................................................................. Para-fluorofentanyl ......................................................................................................................................................................... Parahexyl ....................................................................................................................................................................................... Phenomorphan .............................................................................................................................................................................. Pholcodine ..................................................................................................................................................................................... Psilocybin ....................................................................................................................................................................................... Psilocyn .......................................................................................................................................................................................... Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5-fluoro-PB-22; 5F-PB-22) .................................................................. Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB–22; QUPIC) ................................................................................................. Tetrahydrocannabinols .................................................................................................................................................................. Thiofentanyl ................................................................................................................................................................................... Tilidine ............................................................................................................................................................................................ VerDate Sep<11>2014 18:31 Oct 05, 2015 Jkt 238001 PO 00000 Frm 00055 Fmt 4703 60403 Sfmt 4703 E:\FR\FM\06OCN1.SGM 06OCN1 2 2 2 2 25 2 2 2 2 25 25 25 25 2 2 2 2 2 4 2 3 70 5 305 25 25 11,000 3,000,000 35 5 5 70,250,000 50 2 2 5 40 658,000 25 10 25 5 2 5 5 350 25 50 50 15 15 100 25 25 25 5 24 24 2 52 2 40 5 5 2 5 30 50 50 50 511,250 2 25 60404 Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices Established 2016 quotas (g) Basic class Trimeperidine ................................................................................................................................................................................. 2 Schedule II 1-Phenylcyclohexylamine .............................................................................................................................................................. 1-Piperidinocyclohexanecarbonitrile .............................................................................................................................................. 4-Anilino-N-phenethyl-4-piperidine (ANPP) ................................................................................................................................... Alfentanil ........................................................................................................................................................................................ Alphaprodine .................................................................................................................................................................................. Amobarbital .................................................................................................................................................................................... Amphetamine (for conversion) ...................................................................................................................................................... Amphetamine (for sale) ................................................................................................................................................................. Carfentanil ...................................................................................................................................................................................... Cocaine .......................................................................................................................................................................................... Codeine (for conversion) ............................................................................................................................................................... Codeine (for sale) .......................................................................................................................................................................... Dextropropoxyphene ...................................................................................................................................................................... Dihydrocodeine .............................................................................................................................................................................. Dihydroetorphine ............................................................................................................................................................................ Diphenoxylate (for conversion) ...................................................................................................................................................... Diphenoxylate (for sale) ................................................................................................................................................................. Ecgonine ........................................................................................................................................................................................ Ethylmorphine ................................................................................................................................................................................ Etorphine hydrochloride ................................................................................................................................................................. Fentanyl ......................................................................................................................................................................................... Glutethimide ................................................................................................................................................................................... Hydrocodone (for conversion) ....................................................................................................................................................... Hydrocodone (for sale) .................................................................................................................................................................. Hydromorphone ............................................................................................................................................................................. Isomethadone ................................................................................................................................................................................ Levo-alphacetylmethadol (LAAM) .................................................................................................................................................. Levomethorphan ............................................................................................................................................................................ Levorphanol ................................................................................................................................................................................... Lisdexamfetamine .......................................................................................................................................................................... Meperidine ..................................................................................................................................................................................... Meperidine Intermediate-A ............................................................................................................................................................ Meperidine Intermediate-B ............................................................................................................................................................ Meperidine Intermediate-C ............................................................................................................................................................ Metazocine ..................................................................................................................................................................................... Methadone (for sale) ..................................................................................................................................................................... Methadone Intermediate ................................................................................................................................................................ Methamphetamine ......................................................................................................................................................................... 5 5 2,950,000 17,750 3 25,125 15,000,000 39,705,000 19 200,000 50,000,000 63,900,000 45 226,375 3 31,250 1,337,500 125,000 3 3 2,300,000 3 235,000 88,500,000 8,250,000 5 4 30 7,125 29,750,000 5,450,000 6 11 6 19 31,875,000 34,375,000 2,061,375 tkelley on DSK3SPTVN1PROD with NOTICES [1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 750,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)] Methylphenidate ............................................................................................................................................................................. Morphine (for conversion) .............................................................................................................................................................. Morphine (for sale) ........................................................................................................................................................................ Nabilone ......................................................................................................................................................................................... Noroxymorphone (for conversion) ................................................................................................................................................. Noroxymorphone (for sale) ............................................................................................................................................................ Opium (powder) ............................................................................................................................................................................. Opium (tincture) ............................................................................................................................................................................. Oripavine ........................................................................................................................................................................................ Oxycodone (for conversion) .......................................................................................................................................................... Oxycodone (for sale) ..................................................................................................................................................................... Oxymorphone (for conversion) ...................................................................................................................................................... Oxymorphone (for sale) ................................................................................................................................................................. Pentobarbital .................................................................................................................................................................................. Phenazocine .................................................................................................................................................................................. Phencyclidine ................................................................................................................................................................................. Phenmetrazine ............................................................................................................................................................................... Phenylacetone ............................................................................................................................................................................... Racemethorphan ........................................................................................................................................................................... Racemorphan ................................................................................................................................................................................ Remifentanil ................................................................................................................................................................................... Secobarbital ................................................................................................................................................................................... Sufentanil ....................................................................................................................................................................................... Tapentadol ..................................................................................................................................................................................... Thebaine ........................................................................................................................................................................................ VerDate Sep<11>2014 18:31 Oct 05, 2015 Jkt 238001 PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 E:\FR\FM\06OCN1.SGM 06OCN1 96,750,000 91,250,000 62,500,000 18,750 17,500,000 1,475,000 112,500 687,500 30,000,000 6,250,000 139,150,000 29,000,000 7,750,000 38,125,000 6 50 3 50 3 3 3,750 215,003 6,255 25,500,000 125,000,000 60405 Federal Register / Vol. 80, No. 193 / Tuesday, October 6, 2015 / Notices Established 2016 quotas (g) Basic class List I Chemicals Ephedrine (for conversion) ............................................................................................................................................................ Ephedrine (for sale) ....................................................................................................................................................................... Phenylpropanolamine (for conversion) .......................................................................................................................................... Phenylpropanolamine (for sale) ..................................................................................................................................................... Pseudoephedrine (for conversion) ................................................................................................................................................ Pseudoephedrine (for sale) ........................................................................................................................................................... The Administrator also establishes aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Administrator may adjust the 2016 aggregate production quotas and assessment of annual needs as needed. Dated: September 30, 2015. Chuck Rosenberg, Acting Administrator. [FR Doc. 2015–25373 Filed 10–5–15; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Foreign Claims Settlement Commission [F.C.S.C. Meeting and Hearing Notice No. 09–15] tkelley on DSK3SPTVN1PROD with NOTICES Sunshine Act Meeting The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR 503.25) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of open meetings as follows: Thursday, October 15, 2015: 10 a.m.— Issuance of Proposed Decisions in claims against Libya. Status: Open All meetings are held at the Foreign Claims Settlement Commission, 600 E Street NW., Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, may be directed to: Patricia M. Hall, Foreign Claims Settlement Commission, 600 E Street NW., Suite 6002, Washington, DC 20579. Telephone: (202) 616–6975. Brian M. Simkin, Chief Counsel. BILLING CODE 4410–BA–P 18:31 Oct 05, 2015 To submit comments: Notice of Lodging of Proposed Consent Decree Under the Clean Air Act On September 29, 2015, the Department of Justice lodged a proposed consent decree with the United States District Court for the Eastern District of Michigan in the lawsuit entitled United States v. Guardian Industries Corp., Civil Action No. 2:15-cv-13426. The United States filed this lawsuit under the Clean Air Act. The complaint seeks injunctive relief and civil penalties for violations of the Clean Air Act’s Prevention of Significant Deterioration requirements at eight float glass manufacturing furnaces owned and operated by the defendant, Guardian Industries Corp., in Kingsburg, California; DeWitt, Iowa; Carleton, Michigan; Geneva, New York; Floreffe, Pennsylvania; Richburg, South Carolina; and Corsicana, Texas. The consent decree requires the defendant to perform injunctive relief, which includes complying with emission limitations that are comprised of numerical or work practice standards that together apply continuously at all times. The defendant will also pay a $312,000 civil penalty and perform a $150,000 wood burning appliance replacement mitigation project in the San Joaquin Valley area in California. The publication of this notice opens a period for public comment on the proposed consent decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and should refer to United States v. Guardian Industries Corp., D.J. Ref. No. 90–5–2– 1–11128. All comments must be submitted no later than thirty (30) days after the publication date of this notice. Comments may be submitted either by email or by mail: Jkt 238001 To submit comments: Send them to: By email ....... [FR Doc. 2015–25500 Filed 10–2–15; 4:15 pm] VerDate Sep<11>2014 DEPARTMENT OF JUSTICE pubcomment-ees.enrd@ usdoj.gov. PO 00000 Frm 00057 Fmt 4703 Sfmt 4703 100,000 4,000,000 22,400,000 8,500,000 7,000 224,500,000 Send them to: By mail ......... Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, D.C. 20044–7611. During the public comment period, the proposed consent decree may be examined and downloaded at this Justice Department Web site: https:// www.justice.gov/enrd/consent-decrees. We will provide a paper copy of the proposed consent decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ— ENRD, P.O. Box 7611, Washington, DC 20044–7611. Please enclose a check or money order for $24.25 (25 cents per page reproduction cost) payable to the United States Treasury. For a paper copy without the exhibits and signature pages, the cost is $19.50. Maureen M. Katz, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2015–25339 Filed 10–5–15; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF LABOR Employee Benefits Security Administration 179th Meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans; Notice of Meeting Pursuant to the authority contained in Section 512 of the Employee Retirement Income Security Act of 1974 (ERISA), 29 U.S.C. 1142, the 179th open meeting of the Advisory Council on Employee Welfare and Pension Benefit Plans (also known as the ERISA Advisory Council) will be held on November 3–4, 2015. The meeting will take place in C5320 Room 6, U.S. Department of Labor, 200 Constitution Avenue NW., Washington, DC 20210 on November 3, from 1 p.m. to approximately 5:00 p.m. On E:\FR\FM\06OCN1.SGM 06OCN1

Agencies

[Federal Register Volume 80, Number 193 (Tuesday, October 6, 2015)]
[Notices]
[Pages 60400-60405]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-25373]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-420F]


Established Aggregate Production Quotas for Schedule I and II 
Controlled Substances and Assessment of Annual Needs for the List I 
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2016

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final order.

-----------------------------------------------------------------------

SUMMARY: This final order establishes the initial 2016 aggregate 
production quotas for controlled substances in schedules I and II of 
the Controlled Substances Act (CSA) and the assessment of annual needs 
for the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine.

DATES: Effective October 6, 2015.

FOR FURTHER INFORMATION CONTACT: John R. Scherbenske, Office of 
Diversion Control, Drug Enforcement Administration, 8701 Morrissette 
Drive, Springfield, VA 22152, Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION:

Legal Authority

    The Drug Enforcement Administration (DEA) implements and enforces 
titles II and III of the Comprehensive Drug Abuse Prevention and 
Control Act of 1970, as amended. Titles II and III are referred to as 
the ``Controlled Substances Act'' and the ``Controlled Substances 
Import and Export Act,'' respectively, and are collectively referred to 
as the ``Controlled Substances Act'' or the ``CSA'' for the purpose of 
this action. 21

[[Page 60401]]

U.S.C. 801-971. The DEA publishes the implementing regulations for 
these statutes in title 21 of the Code of Federal Regulations (CFR), 
chapter II. The CSA and its implementing regulations are designed to 
prevent, detect, and eliminate the diversion of controlled substances 
and listed chemicals into the illicit market while ensuring an adequate 
supply is available for the legitimate medical, scientific, research, 
and industrial needs of the United States. Controlled substances have 
the potential for abuse and dependence and are controlled to protect 
the public health and safety.
    Section 306 of the Controlled Substances Act (CSA), 21 U.S.C. 826, 
requires the Attorney General to determine the total quantity and 
establish production quotas for each basic class of controlled 
substance in schedules I and II and for ephedrine, pseudoephedrine, and 
phenylpropanolamine to be manufactured each calendar year to provide 
for the estimated medical, scientific, research, and industrial needs 
of the United States, for lawful export requirements, and for the 
establishment and maintenance of reserve stocks. This responsibility 
has been delegated to the Administrator of the DEA through 28 CFR 
0.100(b).

Background

    The 2016 aggregate production quotas and assessment of annual needs 
represent those quantities of schedule I and II controlled substances 
and the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine that may be manufactured in the United States in 
2016 to provide for the estimated medical, scientific, research, and 
industrial needs of the United States, lawful export requirements, and 
the establishment and maintenance of reserve stocks. These quotas 
include imports of ephedrine, pseudoephedrine, and phenylpropanolamine 
but do not include imports of controlled substances for use in 
industrial processes.
    On July 17, 2015, a notice titled, ``Proposed Aggregate Production 
Quotas for Schedule I and II Controlled Substances and Proposed 
Assessment of Annual Needs for the List I Chemicals Ephedrine, 
Pseudoephedrine, and Phenylpropanolamine for 2016'' was published in 
the Federal Register. 80 FR 42540. This notice proposed the 2016 
aggregate production quotas for each basic class of controlled 
substance listed in schedules I and II and the 2016 assessment of 
annual needs for the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine. All interested persons were invited to comment on 
or object to the proposed aggregate production quotas and the proposed 
assessment of annual needs on or before August 17, 2015.

Comments Received

    Twenty comments were received from four DEA-registered 
manufacturers within the published comment period regarding 17 
different schedule I and II controlled substances. The DEA did not 
receive any comments regarding the proposed assessment of annual needs 
for the list I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine. Commenters stated that the proposed aggregate 
production quotas for [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-
1-yl)methanone (THJ-2201), amphetamine (for sale), codeine (for sale), 
gamma hydroxybutric acid, levorphanol, marihuana, methylphenidate, N-
(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide (ADB-PINACA), N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA), N-(1-Amino-3-
methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
(AB-CHMINACA), N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide (AB-PINACA), N-(1-phenethylpiperidin-4-yl)-N-
phenylacetamide (acetyl fentanyl), nabilone, oxymorphone (for 
conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-fluoropentyl)-
1H-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-yl 1-pentyl-
1H-indole-3-carboxylate (PB-22) were insufficient to provide for the 
estimated medical, scientific, research, and industrial needs of the 
United States, export requirements, and the establishment and 
maintenance of reserve stocks.

Determination of 2016 Aggregate Production Quotas and Assessment of 
Annual Needs

    In determining the 2016 aggregate production quotas and assessment 
of annual needs, the DEA has taken into consideration the above 
comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 
1315.11, in accordance with 21 U.S.C. 826(a), and other relevant 
factors, including the 2015 manufacturing quotas, current 2015 sales 
and inventories, anticipated 2016 export requirements, industrial use, 
additional applications for 2016 quotas, as well as information on 
research and product development requirements. Based on this 
information, the DEA has determined that adjustments to the proposed 
aggregate production quotas for codeine (for sale), hydromorphone, 
marihuana, methylphenidate, and N-(1-phenethylpiperidin-4-yl)-N-
phenylacetamide (acetyl fentanyl) are warranted. This final order 
reflects those adjustments.
    Regarding [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
yl)methanone (THJ-2201), amphetamine (for sale), gamma hydroxybutric 
acid, levorphanol, N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-
1H-indazole-3-carboxamide (ADB-PINACA), N-(1-Amino-3-methyl-1-oxobutan-
2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA), N-(1-
Amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-
carboxamide (AB-CHMINACA), N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
pentyl-1H-indazole-3-carboxamide (AB-PINACA), nabilone, oxymorphone 
(for conversion), oxymorphone (for sale), Quinolin-8-yl 1-(5-
fluoropentyl)-1H-indole-3-carboxylate (5-Flouro-PB-22), and Quinolin-8-
yl 1-pentyl-1H-indole-3-carboxylate (PB-22), the DEA has determined 
that the proposed aggregate production quotas are sufficient to provide 
for the 2016 estimated medical, scientific, research, and industrial 
needs of the United States, export requirements, and the establishment 
and maintenance of reserve stocks. This final order establishes these 
aggregate production quotas at the same amounts as proposed.
    As described in the previously published notice proposing the 2016 
aggregate production quotas and assessment of annual needs, the DEA has 
specifically considered that inventory allowances granted to individual 
manufacturers may not always result in the availability of sufficient 
quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 
826(a), as intended. See 21 CFR 1303.24. This would be concerning if a 
natural disaster or other unforeseen event resulted in substantial 
disruption to the amount of controlled substances available to provide 
for legitimate public need. As such, the DEA has included in all 
established schedule II aggregate production quotas, and certain 
schedule I aggregate production quotas, an additional 25% of the 
estimated medical, scientific, and research needs as part of the amount 
necessary to ensure the establishment and maintenance of reserve 
stocks. The established aggregate production quotas will reflect these 
included amounts. This action will not affect the ability of

[[Page 60402]]

manufacturers to maintain inventory allowances as specified by 
regulation. The DEA expects that maintaining this reserve in certain 
established aggregate production quotas will mitigate adverse public 
effects if an unforeseen event results in the substantial disruption to 
the amount of controlled substances available to provide for legitimate 
public need, as determined by the DEA. The DEA does not anticipate 
utilizing the reserve in the absence of these circumstances.
    In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 
1315.11, the Administrator hereby establishes the 2016 aggregate 
production quotas for the following schedule I and II controlled 
substances and the 2016 assessment of annual needs for the list I 
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 
expressed in grams of anhydrous acid or base, as follows:

------------------------------------------------------------------------
                                                        Established 2016
                     Basic class                           quotas (g)
------------------------------------------------------------------------
                               Schedule I
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-                                     25
 tetramethylcyclopropyl)methanone (UR-144)...........
[1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-                    15
 yl)methanone (THJ-2201).............................
[1-(5-Fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-                          25
 tetramethylcyclopropyl)methanone (XLR11)............
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)butan-1-one                   25
 (butylone)..........................................
1-(1,3-Benzodioxol-5-yl)-2-(methylamino)pentan-1-one                  25
 (pentylone).........................................
1-(1-Phenylcyclohexyl)pyrrolidine....................                 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)....                 45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)...                 45
1-[1-(2-Thienyl)cyclohexyl]piperidine................                 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-                45
 200)................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073)..............                 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-                45
 18 and RCS-8).......................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)..............                 45
1-Methyl-4-phenyl-4-propionoxypiperidine.............                  2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)...                 45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)....                 45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)...                 45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)....                 45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)....                 45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4)                 45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)..                 45
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E).....                 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)....                 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)....                 30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C-P)..                 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H).............                 30
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-                                 25
 methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe;
 25B; Cimbi-36)......................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)....                 30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-                                25
 methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe;
 25C; Cimbi-82)......................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)......                 30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-                                  15
 methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe;
 25I; Cimbi-5).......................................
2-(Methylamino)-1-phenylpentan-1-one (pentedrone)....                 25
2,5-Dimethoxy-4-ethylamphetamine (DOET)..............                 25
2,5-Dimethoxy-4-n-propylthiophenethylamine...........                 25
2,5-Dimethoxyamphetamine.............................                 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-                30
 2)..................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine                   30
 (2C-T-4)............................................
3,4,5-Trimethoxyamphetamine..........................                 25
3,4-Methylenedioxyamphetamine (MDA)..................                 55
3,4-Methylenedioxymethamphetamine (MDMA).............                 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA).........                 40
3,4-Methylenedioxy-N-methylcathinone (methylone).....                 50
3,4-Methylenedioxypyrovalerone (MDPV)................                 35
3-Fluoro-N-methylcathinone (3-FMC)...................                 25
3-Methylfentanyl.....................................                  2
3-Methylthiofentanyl.................................                  2
4-Bromo-2,5-dimethoxyamphetamine (DOB)...............                 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)...........                 25
4-Fluoro-N-methylcathinone (4-FMC)...................                 25
4-Methoxyamphetamine.................................                150
4-Methyl-2,5-dimethoxyamphetamine (DOM)..............                 25
4-Methylaminorex.....................................                 25
4-Methyl-N-ethylcathinone (4-MEC)....................                 25
4-Methyl-N-methylcathinone (mephedrone)..............                 45
4-Methyl-[alpha]-pyrrolidinopropiophenone (4-MePPP)..                 25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-                                  68
 hydroxycyclohexyl]-phenol...........................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-                53
 phenol (cannabicyclohexanol or CP-47,497 C8-homolog)
5-Methoxy-3,4-methylenedioxyamphetamine..............                 25
5-Methoxy-N,N-diisopropyltryptamine..................                 25
5-Methoxy-N,N-dimethyltryptamine.....................                 25
Acetyl-alpha-methylfentanyl..........................                  2

[[Page 60403]]

 
Acetyldihydrocodeine.................................                  2
Acetylmethadol.......................................                  2
Allylprodine.........................................                  2
Alphacetylmethadol...................................                  2
alpha-Ethyltryptamine................................                 25
Alphameprodine.......................................                  2
Alphamethadol........................................                  2
alpha-Methylfentanyl.................................                  2
alpha-Methylthiofentanyl.............................                  2
alpha-Methyltryptamine (AMT).........................                 25
alpha-Pyrrolidinobutiophenone ([alpha]-PBP)..........                 25
alpha-Pyrrolidinopentiophenone ([alpha]-PVP).........                 25
Aminorex.............................................                 25
Benzylmorphine.......................................                  2
Betacetylmethadol....................................                  2
beta-Hydroxy-3-methylfentanyl........................                  2
beta-Hydroxyfentanyl.................................                  2
Betameprodine........................................                  2
Betamethadol.........................................                  4
Betaprodine..........................................                  2
Bufotenine...........................................                  3
Cathinone............................................                 70
Codeine methylbromide................................                  5
Codeine-N-oxide......................................                305
Desomorphine.........................................                 25
Diethyltryptamine....................................                 25
Difenoxin............................................             11,000
Dihydromorphine......................................          3,000,000
Dimethyltryptamine...................................                 35
Dipipanone...........................................                  5
Fenethylline.........................................                  5
gamma-Hydroxybutyric acid............................         70,250,000
Heroin...............................................                 50
Hydromorphinol.......................................                  2
Hydroxypethidine.....................................                  2
Ibogaine.............................................                  5
Lysergic acid diethylamide (LSD).....................                 40
Marihuana............................................            658,000
Mescaline............................................                 25
Methaqualone.........................................                 10
Methcathinone........................................                 25
Methyldesorphine.....................................                  5
Methyldihydromorphine................................                  2
Morphine methylbromide...............................                  5
Morphine methylsulfonate.............................                  5
Morphine-N-oxide.....................................                350
N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide                    25
 (AKB48).............................................
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-                 50
 indazole-3-carboxamide (ADB-PINACA).................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-                            50
 fluorobenzyl)-1H-indazole-3-carboxamide (AB-
 FUBINACA)...........................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-                               15
 (cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-
 CHMINACA)...........................................
N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-                     15
 indazole-3-carboxamide (AB-PINACA)..................
N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide                      100
 (acetyl fentanyl)...................................
N,N-Dimethylamphetamine..............................                 25
Naphthylpyrovalerone (naphyrone).....................                 25
N-Benzylpiperazine...................................                 25
N-Ethyl-1-phenylcyclohexylamine......................                  5
N-Ethylamphetamine...................................                 24
N-Hydroxy-3,4-methylenedioxyamphetamine..............                 24
Noracymethadol.......................................                  2
Norlevorphanol.......................................                 52
Normethadone.........................................                  2
Normorphine..........................................                 40
Para-fluorofentanyl..................................                  5
Parahexyl............................................                  5
Phenomorphan.........................................                  2
Pholcodine...........................................                  5
Psilocybin...........................................                 30
Psilocyn.............................................                 50
Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-                         50
 carboxylate (5-fluoro-PB-22; 5F-PB-22)..............
Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-                   50
 22; QUPIC)..........................................
Tetrahydrocannabinols................................            511,250
Thiofentanyl.........................................                  2
Tilidine.............................................                 25

[[Page 60404]]

 
Trimeperidine........................................                  2
------------------------------------------------------------------------
                               Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine..............................                  5
1-Piperidinocyclohexanecarbonitrile..................                  5
4-Anilino-N-phenethyl-4-piperidine (ANPP)............          2,950,000
Alfentanil...........................................             17,750
Alphaprodine.........................................                  3
Amobarbital..........................................             25,125
Amphetamine (for conversion).........................         15,000,000
Amphetamine (for sale)...............................         39,705,000
Carfentanil..........................................                 19
Cocaine..............................................            200,000
Codeine (for conversion).............................         50,000,000
Codeine (for sale)...................................         63,900,000
Dextropropoxyphene...................................                 45
Dihydrocodeine.......................................            226,375
Dihydroetorphine.....................................                  3
Diphenoxylate (for conversion).......................             31,250
Diphenoxylate (for sale).............................          1,337,500
Ecgonine.............................................            125,000
Ethylmorphine........................................                  3
Etorphine hydrochloride..............................                  3
Fentanyl.............................................          2,300,000
Glutethimide.........................................                  3
Hydrocodone (for conversion).........................            235,000
Hydrocodone (for sale)...............................         88,500,000
Hydromorphone........................................          8,250,000
Isomethadone.........................................                  5
Levo-alphacetylmethadol (LAAM).......................                  4
Levomethorphan.......................................                 30
Levorphanol..........................................              7,125
Lisdexamfetamine.....................................         29,750,000
Meperidine...........................................          5,450,000
Meperidine Intermediate-A............................                  6
Meperidine Intermediate-B............................                 11
Meperidine Intermediate-C............................                  6
Metazocine...........................................                 19
Methadone (for sale).................................         31,875,000
Methadone Intermediate...............................         34,375,000
Methamphetamine......................................          2,061,375
------------------------------------------------------------------------
  [1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
 non-prescription product; 750,000 grams for methamphetamine mostly for
       conversion to a schedule III product; and 61,375 grams for
                       methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate......................................         96,750,000
Morphine (for conversion)............................         91,250,000
Morphine (for sale)..................................         62,500,000
Nabilone.............................................             18,750
Noroxymorphone (for conversion)......................         17,500,000
Noroxymorphone (for sale)............................          1,475,000
Opium (powder).......................................            112,500
Opium (tincture).....................................            687,500
Oripavine............................................         30,000,000
Oxycodone (for conversion)...........................          6,250,000
Oxycodone (for sale).................................        139,150,000
Oxymorphone (for conversion).........................         29,000,000
Oxymorphone (for sale)...............................          7,750,000
Pentobarbital........................................         38,125,000
Phenazocine..........................................                  6
Phencyclidine........................................                 50
Phenmetrazine........................................                  3
Phenylacetone........................................                 50
Racemethorphan.......................................                  3
Racemorphan..........................................                  3
Remifentanil.........................................              3,750
Secobarbital.........................................            215,003
Sufentanil...........................................              6,255
Tapentadol...........................................         25,500,000
Thebaine.............................................        125,000,000
------------------------------------------------------------------------

[[Page 60405]]

 
                            List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)...........................            100,000
Ephedrine (for sale).................................          4,000,000
Phenylpropanolamine (for conversion).................         22,400,000
Phenylpropanolamine (for sale).......................          8,500,000
Pseudoephedrine (for conversion).....................              7,000
Pseudoephedrine (for sale)...........................        224,500,000
------------------------------------------------------------------------

    The Administrator also establishes aggregate production quotas for 
all other schedule I and II controlled substances included in 21 CFR 
1308.11 and 1308.12 at zero. In accordance with 21 CFR 1303.13 and 21 
CFR 1315.13, upon consideration of the relevant factors, the 
Administrator may adjust the 2016 aggregate production quotas and 
assessment of annual needs as needed.

    Dated: September 30, 2015.
Chuck Rosenberg,
Acting Administrator.
[FR Doc. 2015-25373 Filed 10-5-15; 8:45 am]
 BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.